Cardiothyreosis

Area of Science:

• Cardiology
• Endocrinology
• Pathophysiology

Background:

• Thyrotoxicosis significantly impacts cardiovascular function, leading to a hyperkinetic syndrome.
• The earliest sign is increased beta-receptors, supported by energy synthesis, but excessive adrenergic action impairs cardiac performance.
• Ultrastructural damage, including mitochondrial dysfunction and myofibril lysis, occurs despite reduced coronary atherosclerosis.

Purpose of the Study:

• To discuss the physiopathology, clinical manifestations, and therapeutic strategies for cardiothyreosis.
• To elucidate the mechanisms behind thyrotoxicosis-induced cardiac dysfunction.
• To outline current treatment approaches for managing the cardiac effects of hyperthyroidism.

Main Methods:

• Review of physiopathology, clinical presentation, and therapy of cardiothyreosis.
• Analysis of beta-receptor activity, ATP/creatine phosphate synthesis, and mitochondrial function.
• Examination of clinical data on incidence, age-related severity, and specific cardiac pathologies like arrhythmias and mitral valve prolapse.

Main Results:

• Cardiothyreosis incidence increases with age and pre-existing cardiovascular disease, affecting 25% of patients over 27.
• Tachyarrhythmias are a major concern, leading to heart failure, thromboembolism, and ventricular fibrillation.
• Thyrotoxicosis can cause papillary muscle dysfunction and mitral valve prolapse, which are reversible in children.

Conclusions:

• Effective treatment of cardiothyreosis requires addressing the underlying etiology, preferably with medical therapy followed by surgery or radioactive iodine.
• Propranolol is crucial for managing catecholamine excess, with adjusted dosages for the elderly.
• Verapamil and anticoagulants are valuable adjuncts for specific arrhythmias and embolic risk reduction, particularly in elderly patients.